Pharmacy Plus has set a new standard in prostate health care with the launch of Duostam, an innovative treatment for Benign Prostatic Hyperplasia (BPH), commonly referred to as prostate enlargement.
The groundbreaking medication was unveiled during the 97th Pharmaceutical Society of Nigeria (PSN) Conference in Uyo, Akwa Ibom, highlighting the company’s commitment to addressing significant health challenges.
BPH, a non-cancerous condition marked by the enlargement of the prostate gland, often leads to Lower Urinary Tract Symptoms (LUTS), which significantly affect the quality of life for many aging men.
Professor Ikenna Nnabugwu, a keynote speaker at the event, noted that LUTS/BPH affects nearly 20 per cent of men over the age of 40, underscoring the urgent need for effective treatment options.
Duostam, the latest addition to Pharmacy Plus’ portfolio, offers a targeted approach to managing BPH. It addresses critical symptoms, slows disease progression, reduces the risk of complications such as acute urinary retention, and minimizes bleeding associated with an enlarged prostate.
Managing director of Pharmacy Plus, Chukwuemeka Obi, emphasised the significance of this innovation. “At Pharmacy Plus, we are dedicated to delivering research-driven solutions that transform lives. Duostam is not only safe but also clinically proven to be effective when used as prescribed,” he said.
The launch of Duostam reinforces Pharmacy Plus’s role as a pioneer in the pharmaceutical industry, bringing hope and improved quality of life to countless men living with BPH. The company continues to focus on advancing healthcare through innovation and patient-centered solutions.
